The findings of the internal cohort exploration and external cohort validation indicated that dacomitinib had an efficacy advantage over afatinib in patients with NSCLC carrying uncommon EGFR mutations with a manageable safety profile, which warrants further clinical exploration and confirmation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.